Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $13.0 million.

  • Celldex Therapeutics' Net Cash Flow rose 30529.97% to $13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$384000.0, marking a year-over-year decrease of 10251.56%. This contributed to the annual value of -$6.5 million for FY2024, which is 22033.43% down from last year.
  • According to the latest figures from Q3 2025, Celldex Therapeutics' Net Cash Flow is $13.0 million, which was up 30529.97% from $5.9 million recorded in Q2 2025.
  • Celldex Therapeutics' Net Cash Flow's 5-year high stood at $80.3 million during Q1 2024, with a 5-year trough of -$72.3 million in Q2 2024.
  • Over the past 5 years, Celldex Therapeutics' median Net Cash Flow value was -$6.3 million (recorded in 2024), while the average stood at -$411631.6.
  • Per our database at Business Quant, Celldex Therapeutics' Net Cash Flow plummeted by 93330.12% in 2023 and then skyrocketed by 30529.97% in 2025.
  • Over the past 5 years, Celldex Therapeutics' Net Cash Flow (Quarter) stood at -$33.0 million in 2021, then skyrocketed by 132.83% to $10.8 million in 2022, then rose by 26.13% to $13.7 million in 2023, then crashed by 158.95% to -$8.1 million in 2024, then soared by 261.39% to $13.0 million in 2025.
  • Its last three reported values are $13.0 million in Q3 2025, $5.9 million for Q2 2025, and -$11.2 million during Q1 2025.